In one of the most closely-watched arenas in biotech, Intellia says its gene editing treatment for a heart muscle ...
Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate ...
AbbVie faced setbacks with emraclidine's dual pivotal trial failures in schizophrenia treatment, impacting their $8.7B ...
Illumina has moved to dismiss a securities lawsuit against the company’s board members over their $8 billion Grail deal, ...
Trump's HHS nominee Robert F. Kennedy Jr., an anti-vaccine advocate calling for stricter pharma oversight, contrasts with ...
EMA's human medicines committee issued positive recommendations for multiple drugs, including Merck's Keytruda and InflaRx's ...
Eyenovia halted Phase 3 trial of atropine-based myopia treatment after data showed it wouldn't meet primary endpoint. CEO ...
Boston Pharmaceuticals succeeded on the two key endpoints for its Phase 2 MASH study, putting the company in contention with ...
Vitalli Bio ends Daewoong deal, Alector receives $50M Hercules Capital loan, Bavarian Nordic gets $340M vaccine orders, Nuvectis Pharma reports disappointing trial data, Flashpoint partners with Saudi ...
Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...
ALX Oncology has found a new chief medical officer, tapping Alan Sandler for the role. Sandler comes to ALX from Mirati, ...
Adaptimmune Therapeutics announces 33% workforce reduction and restructuring to save $300 million through 2028. Company halts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback